Press Releases

2023 Hearst Health Prize - AI for Incidental CAC

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

DASI Simulations' PrecisionTAVI gets CMS Hospital Outpatient Billing Code

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

Echo IQ's breakthrough research on cardiovascular health continues with unveiling of AI-driven aortic stenosis and mitral regurgitation detection results at ESC 2023 Congress

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

Keystone Perfusion Services, PC recognized for life-saving contribution during COVID-19 pandemic, secures fifth consecutive year on Inc. 5000 list

Aug 15, 2023 | Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

Corazon and the Society for Cardiovascular Angiography and Interventions announce partnership

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta announces SpotLight Duo, the world’s first dedicated cardiovascular and thoracic CT system

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

Study Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram View

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately.

Cassling connects cardiologists with revolutionary AI software

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

DASI Simulation’s Precision TAVI earns FDA clearance

Jun 14, 2023 | Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

RecoverRite®, American College of Cardiology Collaborate to Change the Face of Cardiovascular Patient Education

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

Study shows PulseAI’s deep learning algorithm outperforms the Apple Watch ECG algorithm in detecting atrial fibrillation

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

$20M gift announced by the Rooney Foundation in support of enhanced cardiac care at NCH

NAPLES, Fla. – February 20, 2023 The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney. In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NCH announces second historic gift in as many weeks totaling a record $40M in support of enhanced care

NAPLES, Fla. – February 21, 2023 On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard. This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida. Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

Patient Image Exchange puts patients 'in the driver’s seat'

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

Ancora Heart appoints David J. Tucker as chief financial officer

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure presents data successfully identifying responders and non-responders to renal denervation using genetic screening

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Cardiac Insight Comments on CMS Announcement of National Payment Rates for Long-Term Continuous ECG (LT-ECG) Monitoring in 2023

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

Procella Therapeutics and Smartwise Enter Collaboration With AstraZeneca to Develop Novel Cardiovascular and Catheter-based Therapies

STOCKHOLM, May 7, 2018 — In patients who have suffered from a heart attack, a large portion of heart cells die, which may cause heart failure and significant mortality and morbidity. The aim of the collaboration with the global biopharmaceutical company AstraZeneca is to develop new ways of regenerating parts of the heart muscle that have been damaged by a heart attack, using Procella Therapeutics' stem cell technology, as well as novel catheter injection methods, using Smartwise's Extroducer catheter.

Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter

ABBOTT PARK, Ill., May 3, 2018 — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analyzing data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue.

Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

James Min named editor-in-chief of Journal of Cardiovascular Computed Tomography

Vienna, VA (April 25, 2017) — James K. Min, MD, FSCCT, has been selected for a five-year term as the new editor-in-chief of the Journal of Cardiovascular Computed Tomography (JCCT). He in turn has named Todd C. Villines, MD, FSCCT, as executive editor along with Gudrun Feuchtner, MD.

Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes

TITUSVILLE, N.J., April 27, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results of a real-world study showing that adults with type 2 diabetes initiated on INVOKANA® (canagliflozin) 300mg had significantly better blood glucose control, based on A1C goal attainment and reduction, compared to similar patients initiated on Farxiga®(dapagliflozin) 10mg.

Two-Year Feasibility Study Results Encouraging with Medtronic Harmony(TM) Transcatheter Pulmonary Valve

DUBLIN and SAN DIEGO — April 26, 2018 — Medtronic plc (NYSE: MDT) today announced two-year outcomes for the Harmony(TM) Transcatheter Pulmonary Valve (TPV) from its early feasibility study. Presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 41st Annual Scientific Sessions, data from 18 patients followed out to two years revealed the Harmony TPV showed solid valve function and no paravalvular leak (PVL).

CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy company using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced first patient enrollment into the pivotal U.S. REFRESH 2-AKI trial.

INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

AUSTIN, Texas, April 12, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced an additional analysis from the landmark CANVAS Program showing INVOKANA® (canagliflozin) improved renal outcomes in people with type 2 diabetes mellitus with or at high risk for cardiovascular disease.

Cardiva Medical® Announces FDA Approval of VASCADE® Vascular Closure System for Use in Femoral Vein Closure

Santa Clara, Calif. — April 5, 2018 — Cardiva Medical®, an innovator in the field of vascular closure, today announced the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE® Vascular Closure System. Already approved for use in arterial closure, VASCADE is now FDA approved for use in 5-7F femoral venous closures as well.

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor

ABBOTT PARK, Ill., March 29, 2018 — Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New York Heart Association (NYHA) Class II – IV heart failure.

BioSig Announces Submission of FDA 510(k) Application for PURE EP(TM) System

Santa Monica, CA, March 28, 2018 — BioSig Technologies, Inc. (OTCQB: BSGM) announced that the Company has filed 510(k) application to the U.S. Food and Drug Administration (FDA) for its first product, PURE EP(TM) System.

Inflammation Testing Prompts Care Changes Leading to Significantly Lower Levels in Patients with Increased Cardiovascular Risk Due to Diabetes or Pre-Diabetes

BOCA RATON, Fla., March 27, 2018 — New research from MDVIP and Cleveland HeartLab finds that patients with diabetes, pre-diabetes or no evidence of diabetes whose physicians ordered myeloperoxidase (MPO) inflammation testing achieved sharp reductions in MPO levels over five years.

Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels.

Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

Edwards Lifesciences Corporation today announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the SAPIEN 3 valve.

Study Shows Positive Results with Medtronic Cryoballoon for Patients with Persistent Atrial Fibrillation

DUBLIN and BARCELONA, Spain - MARCH 19, 2018 - Medtronic plc (NYSE: MDT) today announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance(TM) Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent atrial fibrillation (AF).

Abbott's MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation

ABBOTT PARK, Ill., March 19, 2018 — Abbott today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan granted national reimbursement for the company's MitraClip therapy to treat people with mitral regurgitation, a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward into the heart.

Study adds to understanding about utility of ultra-sensitive cardiac troponin measurement in diagnosing and predicting cardiovascular syndromes

ALAMEDA, Calif., March 13, 2018 — Cardiac troponin I (cTnI) concentrations measured with the Singulex ultrasensitive cTnI assay, powered by Single Molecule Counting technology, were associated with a higher prevalence of coronary artery disease (CAD) and independently predicted cardiovascular events in patients with obstructive and non-obstructive CAD, according to a study published in the Journal of the American Heart Association.

Mardil Medical Announces First Human Implants of the VenTouch® Triad Targeted Ventricular Reshaping System

MINNEAPOLIS, March 14, 2018 — Mardil Medical, Inc., today announced the first human implants of its VenTouch® Triad device. Designed as a combination therapy to simultaneously treat the dilated ventricle and the resulting distorted valve in patients suffering from Type IIIb Functional Mitral Valve Regurgitation (FMR), VenTouch is a less-invasive treatment for a condition that can, if left untreated, accelerate and worsen heart failure.

NQF Issues Vital Guidance to Improve Shared Decision Making Between Patients and Healthcare Providers

Washington, DC—The National Quality Forum (NQF) today issued a call to action to make shared decision making a standard of care for all patients, across settings and conditions. The new guide for healthcare providers, the National Quality Partners Playbook™: Shared Decision Making in Healthcare, offers vital guidance for this process of communication in which clinicians and patients work together to make healthcare decisions that align with what matters most to patients.

New Late-Breaking Study Finds Wearable Electrocardiogram (ECG) Monitoring Patch Can Detect Atrial Fibrillation Earlier and More Efficiently than Routine Care

ORLANDO, Fla., March 10, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced late-breaking results of a new home-based clinical trial showing that a wearable continuous electrocardiogram (ECG) monitoring patch can identify people with asymptomatic atrial fibrillation (AFib) earlier and more efficiently than routine care.